Share The Food and Drug Administration plans to revoke approval of Avastin, a popular drug used to treat metastatic breast cancer. Avastin earned drug maker Hoffman-La Roche nearly $6 billion in 2009, making it a top-seller for the Swiss pharmeceutical company. The FDA gave it the green light in 2008, based on studies indicating...
read moreShare The United States Food and Drug Administration may be gaming with the impression of getting the very uncommon step of withdrawing endorsement of a medicine that patients with higher breast cancer revolve to as a final expectation. This medicine, Avastin, has been recommended to around 17,500 women experiencing from breast...
read moreShare The benefit of using the top-selling cancer drug Avastin for breast cancer was questioned by the Food and Drug Administration. The improvement visible in women given chemotherapy alone and those given with chemotherapy and Avastin is not clinically significant, the agency said. They added that there were more critical side...
read more
|
